(Q33941996)
Statements
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma (English)
Atkins MB
Redman B
Mier J
Gollob J
Weber J
Sosman J
MacPherson BL